Skip to content

A single-center, single-blind, randomized, controlled clinical study on percutaneous auricular vagus nerve stimulation (taVNS) for the treatment of depression with insomnia based on the theory of heart-kidney interaction

A single-center, single-blind, randomized, controlled clinical study on percutaneous auricular vagus nerve stimulation (taVNS) for the treatment of depression with insomnia based on the theory of heart-kidney interaction

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000612
Enrollment
Unknown
Registered
2026-03-19
Start date
2026-04-01
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression accompanied by insomnia

Interventions

Sponsors

The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18–75 years, no gender restrictions. 2. Meets DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) diagnostic criteria for 'Depressive Disorder'. 3. Hamilton Depression Rating Scale (HAMD-17) total score between 17 and 23 points (moderate depression). 4. Meet DSM-5 diagnostic criteria for 'Insomnia Disorder' with a disease duration = 3 months. 5. Pittsburgh Sleep Quality Index (PSQI) score = 8. 6. No use of antidepressants, anxiolytics, or sedative-hypnotics within 2 weeks prior to enrolment; or stable maintenance of such medications for = 4 weeks. 7. Voluntary participation and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Secondary depressive disorder or insomnia arising from organic disease, medication, or psychiatric disorders. 2. Depressive episodes within bipolar affective disorder, or depressive or insomnia symptoms stemming from dysthymic disorder, reactive depression, or other conditions. 3. Severe diseases of vital organs (heart, liver, kidneys) or neurological disorders (e.g., epilepsy). 4. Individuals with implanted electronic devices (e.g., pacemakers, cochlear implants). 5. Presence of skin lesions, infections, or severe dermatological conditions at the treatment site (ear). 6. Pregnant or breastfeeding women. 7. Participants currently enrolled in other clinical trials.

Design outcomes

Primary

MeasureTime frame
Hamilton Depression Scale;Pittsburgh Sleep Quality Index;

Secondary

MeasureTime frame
Insomnia Severity Index Scale;Sleep Diary;Actigraphy;Self-rating Anxiety Scale;Fatigue severity scale;Epworth Sleepiness Scale;Heart rate variability;

Countries

china

Contacts

Public Contactwangcong

The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine

wangcong90s@163.com18357130082

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Apr 4, 2026